Nearly 20 million doses of potentially dangerous medicines prevented from reaching the public
Similar Posts
Government to align with European specifications on high risk in vitro diagnostic devices to reduce regulatory burden
The specifications will establish standards for high-risk diagnostic tests while creating consistency with European regulations
Submission and assessment timetables for innovative medicines applications
Guidance on the deadlines for initial and response submissions.
Research: Report of The Commission on Human Medicines Isotretinoin Implementation Advisory Expert Working Group
Report of Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.
Guidance: Timelines for acceptance of CE marked medical devices in Great Britain (GB)
Transitional arrangements and timelines for acceptance of CE marked medical device in Great Britain.
Guidance: AI Airlock Phase 2 Cohort
Phase 2 of the Airlock will include seven additional technologies spanning AI-powered clinical note taking, advanced cancer diagnostics, eye disease detection tools, and obesity treatment support systems.
MHRA designated as WHO-Listed Authority: a milestone for UK life sciences and global health
WHO recognition affirms MHRA’s commitment to regulatory excellence, innovation and global collaboration